In its latest bid to ensure competition among drug makers, the European Commission has opened a formal investigation into whether Teva Pharmaceutical (TEVA) illegally prevented rival companies from introducing versions of a top-selling medicine.
The probe is focused on two issues. The first is whether Teva used various patent maneuvers to thwart generic manufacturers from being able to market copycat versions of the Copaxone multiple sclerosis treatment. The EC also wants to determine if the drug maker ran a campaign directed at hospitals and doctors to create “false perceptions” of similar multiple sclerosis medicines.
About the Author Reprints
